For context, Tempus uses AI to improve precision medicine solutions, as well as drug discovery and diagnostics. Its operating ...

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. resulting from allegations that Tempus AI ...

An independent safety board has endorsed the continuation of BioXcel Therapeutics, Inc.'s (NASDAQ: BTAI) pivotal Phase 3 SERENITY At-Home trial evaluating BXCL501 for agitation tied to bipolar ...

The act would require all therapy services be conducted by a licensed professional, prohibiting AI from providing direct patient care.

In this video, I will talk about Tempus AI (NASDAQ: TEM) and the recent short-seller report. Watch the short video to learn more, consider subscribing, and click the special offer link below. *Stock ...

Tempus AI is a healthcare-oriented artificial intelligence company. Spruce Point Capital Management released a report ...

The concept of AI in healthcare is no longer a novelty, experts are acknowledging AI algorithms, detection, and drug ...

U.S.-based Tempus AI came under intense pressure after a scathing short seller report raised red flags about the company’s valuation, business model, and financial transparency.

Live Updates Live Coverage Updates appear automatically as they are published. Wall Street Analyst Moves 10:09 am by Gerelyn ...

After a three-year drought, the industry is questioning whether the window for medtech public offerings is open following a ...

The short-sale attack on Tempus AI (TEM) heated up on Wednesday. The stock’s rally halted after it lost 19.23% to close at ...

Spruce Point said Tempus’ revenue quality should be carefully scrutinized, because of signs of "aggressive accounting." ...